Cancer Chemotherapy and Pharmacology

, Volume 54, Issue 6, pp 546–552 | Cite as

Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

  • E. EspinosaEmail author
  • S. Morales
  • P. Borrega
  • A. Casas
  • C. Madroñal
  • I. Machengs
  • J. A. Illarramendi
  • J. Lizón
  • J. A. Moreno
  • J. Belón
  • J. Janáriz
  • M. de la Puente
  • T. Checa
  • J. R. Mel
  • M. González Barón
Original Article



Epirubicin and docetaxel are two of the most active drugs against breast carcinoma. As the achievement of a pathological complete response (pCR) is important for survival of patients with locally advanced disease, we used both drugs as neoadjuvant chemotherapy.

Patients and methods

Women with locally advanced or inflammatory breast cancer received epirubicin 120 mg/m2 followed by docetaxel 75 mg/m2, both on day 1, every 21 days for four cycles. Lenograstim was administered for 10 days in all cycles.


Of 51 patients included, 50 received a total of 188 cycles, with a median of 4 per patient. The median age was 47 years, tumour stage was IIIA in 14 patients and IIIB in 36. Oestrogen receptors were positive in 65% of tumours. There were 10 clinical complete responses (20%) and 29 partial responses (58%). Surgery consisted of mastectomy in 40 patients and tumorectomy in 6. After surgery, 9 pCR were recorded (18%). One patient progressed and died soon after the end of chemotherapy. After a median follow-up of 22 months, the median disease-free survival was 33.7 months. Grade 3/4 neutropenia was observed in 32% of patients, anaemia in 6%, and thrombocytopenia in 4%. Five patients had febrile neutropenia. There were no toxic deaths or grade 4 nonhaematological toxicities.


Docetaxel plus high-dose epirubicin showed promising activity in patients with locally advanced and inflammatory breast cancer, at the cost of moderate toxicity.


Locally advanced breast cancer Epirubicin High-dose Docetaxel Neoadjuvant 



We are indebted to Dr Beatriz Gil-Alberdi for her assistance in preparing the manuscript. The authors acknowledge the work of Biométrica in doing the monitoring and the statistical analysis of the study and Aventis Pharma for the general coordination of the project.


  1. 1.
    Amat S, Bougnoux P, Penault-Llorca F, Fetissof F, Cure H, Kwiatkowski F, Achard JL, Body G, Dauplat J, Chollet P (2003) Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate. Br J Cancer 88:1339–1345CrossRefPubMedGoogle Scholar
  2. 2.
    Baldini E, Gardin G, Giannessi PG, Evangelista G, Roncella M, Prochilo T, Collecchi P, Rosso R, Lionetto R, Bruzzi P, Mosca F, Conte PF (2003) Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: a randomized phase III trial in locally advanced breast cancer. Ann Oncol 14:227–232CrossRefPubMedGoogle Scholar
  3. 3.
    Bonnefoi H, Biganzoli L, Cufer T, Mauriac L, Hamilton A, Schaefer P, Piccart M (2001) An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-FU (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer. Breast Cancer Res Treat 70:55–63CrossRefPubMedGoogle Scholar
  4. 4.
    Cance WG, Carey LA, Calvo BF, Sartor C, Sawyer L, Moore DT, Rosenman J, Ollila DW, Graham 2nd M (2002) Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg 236:295–302; discussion 302–303CrossRefPubMedGoogle Scholar
  5. 5.
    Chollet P, Charrier S, Brain E, Cure H, van Praagh I, Feillel V, de Latour M, Dauplat J, Misset JL, Ferriere JP (1997) Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur J Cancer 33:862–866CrossRefPubMedGoogle Scholar
  6. 6.
    Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, Davidson NE, Martino S, Livingston R, Ingle JN, Perez EA, Carpenter J, Hurd D, Holland JF, Smith BL, Sartor CI, Leung EH, Abrams J, Schilsky RL, Muss HB, Norton L (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439CrossRefPubMedGoogle Scholar
  7. 7.
    Dhingra K, Esparza-Guerra L, Valero V, et al (1999) A phase II randomized trial of dose-intensive, neoadjuvant 5FU, doxorubicin, cyclophosphamide with G-CSF in locally advanced breast cancer. Annual Meeting of the American Society of Clinical Oncology, vol 18. p 74Google Scholar
  8. 8.
    Estévez LG, Cuevas JM, Antón A, Florián J, López-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J (2003) Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res 9:686–692PubMedGoogle Scholar
  9. 9.
    Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV, Bear HD (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMedGoogle Scholar
  10. 10.
    Fountzilas G, Athanassiades A, Giannakakis T, Briasoulis E, Bafaloukos D, Kalogera-Fountzila A, Onienaoum A, Kalofonos H, Pectasides D, Andreopoulou E, Bamia C, Kosmidis P, Pavlidis N, Skarlos D (1997) A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study. Ann Oncol 8:1213–1220CrossRefPubMedGoogle Scholar
  11. 11.
    Friedrichs K, Holzel F, Janicke F (2002) Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report. Eur J Cancer 38:1730–1738CrossRefPubMedGoogle Scholar
  12. 12.
    Fumoleau P, Kerbrat P, Romestaing P, Fargeot P, Bremond A, Namer M, Schraub S, Goudier MJ, Mihura J, Monnier A, Clavere P, Serin D, Seffert P, Pourny C, Facchini T, Jacquin JP, Sztermer JF, Datchary J, Ramos R, Luporsi E (2003) Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial. J Clin Oncol 21:298–305CrossRefPubMedGoogle Scholar
  13. 13.
    Ganem G, Tubiana-Hulin M, Fumoleau P, Combe M, Misset JL, Vannetzel JM, Bachelot T, De Ybarlucea LR, Lotz V, Bendahmane B, Dieras V (2003) Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer. Ann Oncol 14:1623–1628CrossRefPubMedGoogle Scholar
  14. 14.
    Gebbia V, Blasi L, Borsellino N, Caruso M, Leonardi V, Agostara B, Valenza R (2003) Paclitaxel and epidoxorubicin or doxorubicin versus cyclophosphamide and epidoxorubicin as first-line chemotherapy for metastatic breast carcinoma: a randomised phase II study. Anticancer Res 23:765–771PubMedGoogle Scholar
  15. 15.
    Ghilezan N, Vitoc C, Tanasscu R, et al (1999) Epidoxorubicin and paclitaxel combination in neoadjuvant setting for stage IIB-IIIA breast cancer: preliminary results. Annual Meeting of the American Society of Clinical Oncology, vol 18. p 94Google Scholar
  16. 16.
    van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237PubMedGoogle Scholar
  17. 17.
    Hamm J, Wilson J, Lembersky B, et al (2003) Neoadjuvant chemotherapy with gemcitabine, epirubicin and paclitaxel in locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group. San Antonio Breast Cancer SymposiumGoogle Scholar
  18. 18.
    Honig S (1996) Treatment of metastatic disease. In: Harris J, Lipman M, Morrow M, et al (eds) Diseases of the breast. Lippincott-Raven, Philadelphia, pp 669–734Google Scholar
  19. 19.
    Konig E, Kurbacher C, Schwonzen M, Breidenbach M, Mallmann P (2002) A phase II study of dose-dense docetaxel and mitoxantrone in the treatment of patients with high-risk metastatic breast cancer. Anticancer Drugs 13:827–832CrossRefPubMedGoogle Scholar
  20. 20.
    Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460–469PubMedGoogle Scholar
  21. 21.
    Mamounas EP, Fisher B (2001) Preoperative (neoadjuvant) chemotherapy in patients with breast cancer. Semin Oncol 28:389–399CrossRefPubMedGoogle Scholar
  22. 22.
    de Matteis A, Nuzzo F, D’Aiuto G, Labonia V, Landi G, Rossi E, Mastro AA, Botti G, De Maio E, Perrone F (2002) Docetaxel plus epidoxorubicin as neoadjuvant treatment in patients with large operable or locally advanced carcinoma of the breast: a single-center, phase II study. Cancer 94:895–901CrossRefPubMedGoogle Scholar
  23. 23.
    Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). Ann Oncol 10:47–52CrossRefPubMedGoogle Scholar
  24. 24.
    Mey U, Gorschluter M, Ziske C, Kleinschmidt R, Glasmacher A, Schmidt-Wolf IG (2003) Weekly docetaxel in patients with pretreated metastatic breast cancer: a phase II trial. Anticancer Drugs 14:233–238CrossRefPubMedGoogle Scholar
  25. 25.
    Millá-Santos A, Millá L, Rallo L, Solano V (2001) High-dose epirubicin plus docetaxel at standard dose with lenograstim support as first-line therapy in advanced breast cancer. Am J Clin Oncol 24:138–142CrossRefPubMedGoogle Scholar
  26. 26.
    Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JW, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Aapro M, et al (1999) Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J Clin Oncol 17:1413–1424Google Scholar
  27. 27.
    Petit T, Borel C, Theobald S, Serin D, Rodier JF, Prevot G, Brettes JP, Klein T (2003) Randomized multicentric study of perioperative chemotherapy with mitoxantrone in early breast cancer. Ann Surg Oncol 10:369–375CrossRefPubMedGoogle Scholar
  28. 28.
    Pouillart P, Fumoleau P, Romieu G, et al (1999) Final results of a phase II randomized, parallel study of doxorubicin/cyclophosphamide and doxorubicin/Taxol as neoadjuvant treatment of local-regional breast cancer. Annual Meeting of the American Society of Clinical Oncology, vol 18. p 73Google Scholar
  29. 29.
    Schneeweiss A, Geberth M, Sinn H-P, et al (2003) The triplet gemcitabine, epirubicin and docetaxel as primary systemic chemotherapy in primary breast cancer T2-4,N0-2,M0: final primary endpoint analysis of a multicentric phase I/II trial. San Antonio Breast Cancer SymposiumGoogle Scholar
  30. 30.
    Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456–1466CrossRefPubMedGoogle Scholar
  31. 31.
    Tchen N, Juffs HG, Downie FP, Yi QL, Hu H, Chemerynsky I, Clemons M, Crump M, Goss PE, Warr D, Tweedale ME, Tannock IF (2003) Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175–4183CrossRefPubMedGoogle Scholar
  32. 32.
    Trudeau ME (2001) Optimizing adjuvant breast cancer chemotherapy: rationale for the MA.21 study. Oncology (Huntingt) 15:7–13Google Scholar
  33. 33.
    Valero V, Esteva J, Sahin A, et al (2000) Phase II trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy +/− tamoxifen in locally advanced breast cancer. San Antonio Breast Cancer SymposiumGoogle Scholar
  34. 34.
    Wenzel C, Locker GJ, Pluschnig U, Zielinski CC, Rudas M, Oberhuber G, Gnant MF, Taucher S, Jakesz R, Steger GG (2002) Phase I/II trial of weekly epidoxorubicin and docetaxel (wED) in the neoadjuvant and palliative treatment of patients with breast cancer. Cancer Chemother Pharmacol 50:155–159CrossRefPubMedGoogle Scholar
  35. 35.
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96–102Google Scholar
  36. 36.
    Zambetti M, Moliterni A, Materazzo C, Stefanelli M, Cipriani S, Valagussa P, Bonadonna G, Gianni L (2001) Long-term cardiac sequelae in operable breast cancer patients given adjuvant chemotherapy with or without doxorubicin and breast irradiation. J Clin Oncol 19:37–43PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • E. Espinosa
    • 1
    • 2
    Email author
  • S. Morales
    • 1
  • P. Borrega
    • 1
  • A. Casas
    • 1
  • C. Madroñal
    • 1
  • I. Machengs
    • 1
  • J. A. Illarramendi
    • 1
  • J. Lizón
    • 1
  • J. A. Moreno
    • 1
  • J. Belón
    • 1
  • J. Janáriz
    • 1
  • M. de la Puente
    • 1
  • T. Checa
    • 1
  • J. R. Mel
    • 1
  • M. González Barón
    • 1
  1. 1.Oncopaz Cooperative GroupMadridSpain
  2. 2.Servicio de Oncología MédicaHospital La PazMadridSpain

Personalised recommendations